Latest Biotechnology, Pharmaceutical and Healthcare News - Page: 2 from BioPortfolio

Prosensa Holding B.V. Files Registration Statement for Proposed Initial Public Offering

Leiden, the Netherlands—May 28, 2013 — Prosensa Holding B.V., today announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not been...

OGT launches ground-breaking 58-gene tumour profiling service to predict patient response to cancer treatment

Technology Strategy Board-funded, government-backed assay performs significantly better than standard tests Detects actionable and novel mutations in breast, prostate, ovarian, lung and colorectal cancers Oxford, UK – 28 May 2013 – Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has fu...

Pharmaceutical companies are hiring a little help, and joining with Third Party Logistics (3PL), but are they abandoning too much control over their business

The new report states that use of 3PL companies is a growing trend in the global pharmaceutical supply chain, as cost cutting measures encourage businesses to use outside companies, who can offer services at competitive prices. However, while Direct to Pharmacy (DTP) and Reduced Wholesaler Agreements (RWA) models play a vital role in the UK, other EU countries are boosting their direct sales, an...

Patients suffering from orphan diseases can look forward to a wider range of drug options in the future

The new report* shows that the relatively unsatisfied market for orphan disease drugs could prove to be a big hit for pharmaceutical companies able to improve upon the limited options currently available to patients. GBI Research’s analysis of industry trends suggests that the orphan disease therapeutics market is likely to see a steady increase in value over the forecast period. There a...

Disease-modifying treatments are becoming a reality for Cystic Fibrosis (CF) sufferers, potentially transforming this life-threatening condition into a manageable one

The new report* highlights Vertex Pharmaceuticals’ Kalydeco (ivacaftor), which received Marketing Authorization Approvals (MAA) in the US and EU last year, and represents a milestone in the CF therapeutics market, as we begin to enter an era of personalized medicine. CF is caused by a genetic mutation which leads to the production of thickened sticky secretions in organs with epithelial...

Thomson Reuters Quarterly Report on U.S. Generic Drug Industry

24th May 2013: Thomson Reuters Movers and Shakers quarterly report, focusing on the U.S. generic drug industry.  Movers and Shakers is the best source of information on generic approvals and challenges, notable mergers and acquisitions, and emerging industry trends. Interested in learning more about the latest developments in generics?  Click here to download the latest edition of...

Pfizer Inc: Re-entry to the OTC healthcare market

MarketLine have recently launched a new report - "Pfizer Inc: Re-entry to the OTC healthcare market" Introduction Pfizer, Inc. was originally founded as fine chemicals business. Following a series of product developments and M&A deals the company is now present in 180 countries around the world, and its portfolio includes human and animal biologic, small molecule medicines, vac...

New showcase for Malvern Instruments’ extensive range of GPC/SEC systems and detectors

23 May 2013: Malvern, UK. New pages on the Malvern Instruments website provide information that enables scientists to make informed choices about detector configurations for their specific GPC/SEC applications.  Showcasing the company’s comprehensive range of Viscotek systems and detectors for gel permeation/size exclusion chromatography (GPC/SEC) these pages help analysts to ident...

Respiratory syncytial virus (RSV) infections account for a significant portion of healthcare resources consumed across the US, as the health of vulnerable infants is seriously threatened by the common winter ailment

The new report* looks at respiratory syncytial virus (RSV), one of the most common causes of pediatric respiratory infections. Transmission is seasonal and the virus is spread through the air by an infected individual’s sneeze or cough. Virtually all children will have been infected by age two. The virus usually presents mild cold-like symptoms in most children, but around 1% of sufferers...

The Declining and Rapidly Aging Population Presents Significant Challenges to the Healthcare System and Economy as a Whole

Japan had a population of 127,817,277 in 2011, making it the 10th most populated country in the world (The World Bank, 2012). However, since 2005, as the number of deaths exceeded that of births, the population has declined. Without significant government intervention, the depopulation process is expected to continue. The proportion of people aged 65 or over is 23.3% and projected to reach 29....

Biobetters, drugs that have been improved since their initial incarnations, are demonstrating fantastic growth and leaving their originators well behind

The new report* explains how the more advanced drugs are far outstripping their biologic predecessors in terms of sales and pricing, helping companies maintain revenue at a time when patent expiry is rife. Examples presented in the report include Amgen’s biobetter Neulasta, used for the treatment of neutropenia. It was launched in 2002, 11 years after originator product Neupogen, and gre...

Axxess™ Self-Expanding Bifurcation Drug-Eluting Stent Shown to be Safe and Effective up to Four Years

Paris, France, 18 May 2012 – New long-term data from the DIVERGE study, presented yesterday at EuroPCR 2012 by Dr. John Ormiston, showed that the use of the Axxess™ drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a four-year period. Axxess™ is a self-expanding bifurcation stent which release...

Malvern Instruments specialist will speak at first PDI Science Pharmaceutical Aerosols workshop

22 May 2013: Malvern, UK:  Dr Paul Kippax, Product Group Manager at Malvern Instruments and a specialist in particle characterization, is one of a panel of invited speakers at the first Particle Design Industrialization (PDI) Science workshop on Pharmaceutical Aerosols, to be held on June 24-25, 2013 at Hong Kong University. The workshop, which is affiliated to the inaugural Inhalation A...

Auxogyn Selected to Present at European BioEquity Conference in Stockholm

Menlo Park, CA – May 22 2013 – Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity Conference being held today in Stockholm, Sw...

Phagenesis Expands Series B Financing to $17 million

Manchester, UK – 22 May 2013 − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital. The increased resources will be used to launch the Phagenyx® treatment, which received its CE Mark in 2012, in new territories an...

Download exclusive survey results from emerging markets experts

Emerging markets experts share experience  Last week I asked a sample of people with experience working in industry and healthcare in emerging markets for their opinions. This was to establish to what extent they are comfortable with their market access approaches and payer marketing strategies in the key growth ecomomies. I got some really interesting responses that I would like to s...

Pi2 Solutions Celebrates 10 years with New Corporate Image and Extended Product Range at SLA PHT Meeting in Philadelphia

30 April 2013, London, Philadelphia:  On its tenth anniversary Pi2 introduced its new corporate image and impressive new product developments at the Special Libraries Association PHTD meeting in Philadelphia. “After ten years of unerring focus on product literature databases and workflow solutions for the pharmaceutical industry we felt the need to mark the occasion”, said fo...

Competition Launched to Select the Hottest Five Emerging Companies in the Digital Health Space

London, UK – 21 May 2013 – Connect Digital Health, organisers of the forthcoming Digital Health Forum 2013 (DHF13) to be held in London on 11 June, has launched its ‘Hot 5’ competition. The competition is open to emerging digital health companies, with the five winners gaining free access to the conference to pitch their business ideas to leading digital health investo...

Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million

       Xellia is a leading developer and manufacturer of anti-infective therapies for multi-drug resistant infections. With this acquisition Novo expands its long-term investment portfolio with a further major life-science company in Denmark and will contribute to the future growth of Xellia. Oslo, Norway and Copenhagen, Denmark, May 21 2013 – Xellia Pharmaceuticals...

Precious metal recovery specialist, PhosphonicS, appoints Linda Bell as Chief Executive Officer

International business leader will support next development stage Oxford, UK, 20 May 2013: PhosphonicS Ltd, a leading precious metal recovery specialist, today announced the appointment of Dr Linda Bell as chief executive officer with immediate effect. PhosphonicS uses proprietary chemistry to create ‘scavenger’ products based on functionalised silicas that enable the rec...

Strengthening Big Data in the Pharmaceutical Industry Interview with Sebastien Lefebvre, Head of Architecture R&D at AstraZeneca

21st May 2013: Operating in the pharmaceutical industry requires superior data management and analytics. Pharmaceutical companies must manage large amounts of information regarding products, customers, prescriber behaviors and clinical trials. This data is the foundation for efforts in research and development, forecasting, and sales and marketing. With increasing regulatory pressure, phar...

Malvern Instruments announces global agreement with Proveris Scientific

21 May 2013: Malvern, UK: Malvern Instruments, a leader in the field of pharmaceutical material characterization, has announced a global agreement with Proveris Scientific Corporation, a company with complementary technology for orally inhaled and nasal drug product (OINDP) testing, to provide a complete solution for nasal spray characterization. This solution comprises the SoloTM for Sprayte...

Source BioScience Interim Management Statement

16th May 2013: Source BioScience plc (LSE: SBS), the international diagnostic and genetic analysis services business, today publishes its Interim Management Statement for the year to date. Unless otherwise stated, the financial information referenced below refers to the four months ended 30 April 2013, and the corresponding period last year, this being the latest practicable date to which f...

e-Therapeutics preliminary results for the year ended 31 January 2013.

14 May 2013 – e-Therapeutics plc (“e-Therapeutics”; AIM: ETX), the drug discovery and development company, today announces its preliminary results for the year ended 31 January 2013. Highlights of 2012/13 (* = events after the 31 January 2013 year end; **announced today) Lead cancer drug ETS2101 enters clinic US phase I trial started in patients with brain cancer...

Edison Investment - NovaBay Pharmaceuticals - Q113 sets the scene - Tuning in for a crescendo of data

NovaBay’s Q113 results set the scene for a potentially transformational second half of 2013, with results expected from three Phase II studies of its topical anti-infective, auriclosene (NVC-422). We currently value the company at $71m, or $1.90 per share, but successful outcomes in all three trials (urinary catheter irrigation, impetigo and viral conjunctivitis, in order of increasing val...